EGFR and non-small cell lung carcinoma: Many synthetic compounds that inhibit phosphorylated STAT3 and EGFR tyrosine kinase activity have been shown to be effective in preclinical studies and in clinical trials of advance stages of non-small cell lung cancer, breast, and ovarian cancer [53-55].